Repeated immunotherapy using intratumoural injection with recombinant interleukin-2 and tumour-infiltrating lymphocytes inhibits growth of breast cancer and induces apoptosis of tumour cells
Liu, David L. ; Yang, M. Q. ; Eberhardt, J. LU and Persson, B. LU
(1996)
In Cancer Letters
103(2).
p.131-136
- Abstract
This study tested the effect of repeated intratumoural injection with recombinant interleukin-2 (rIL-2) and tumour-infiltrating lymphocytes (TILs) on inhibition of growth of breast cancer and on induction of apoptosis of tumour cells. The tumour cell line LDLX43 was used to induce breast cancer in Wistar rats. Group I (10 rats) was the control. Group II (12 rats) received repeated intratumoural injection with rIL-2 and TILs, rIL-2 at the dose of 5 x 105 IU/day was given for 7 days, and 1 x 107 TILs were injected on the second day of each rIL-2 therapy, for a treatment session, Overall, two treatment sessions of immunotherapy with rIL-2 and TILs were given in all treated animals. Rapid increased tumour volume was... (More)
This study tested the effect of repeated intratumoural injection with recombinant interleukin-2 (rIL-2) and tumour-infiltrating lymphocytes (TILs) on inhibition of growth of breast cancer and on induction of apoptosis of tumour cells. The tumour cell line LDLX43 was used to induce breast cancer in Wistar rats. Group I (10 rats) was the control. Group II (12 rats) received repeated intratumoural injection with rIL-2 and TILs, rIL-2 at the dose of 5 x 105 IU/day was given for 7 days, and 1 x 107 TILs were injected on the second day of each rIL-2 therapy, for a treatment session, Overall, two treatment sessions of immunotherapy with rIL-2 and TILs were given in all treated animals. Rapid increased tumour volume was found in the control group. In the treated group the total response rate was 42%, of which 25% rumours showed partial regression and 17% tumours reached complete remission where infiltration of plenty of T lymphocytes was detected, indicating that T cell-mediated antitumour immunity is primarily responsible for tumour rejection. Further investigation showed the repeated immunotherapy using intratumoural injection with rIL-2 and TILs could induce the development of apoptosis of breast cancer cells.
(Less)
- author
- Liu, David L.
; Yang, M. Q.
; Eberhardt, J.
LU
and Persson, B.
LU
- publishing date
- 1996-06-05
- type
- Contribution to journal
- publication status
- published
- keywords
- Apoptosis, Breast cancer, Cytokine, Immunohistology, Immunotherapy, Interleukin-2, Tumour-infiltrating lymphocytes
- in
- Cancer Letters
- volume
- 103
- issue
- 2
- pages
- 6 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:0030009332
- pmid:8635148
- ISSN
- 0304-3835
- DOI
- 10.1016/0304-3835(96)04195-X
- language
- English
- LU publication?
- no
- id
- d07b4c00-8159-4b8c-ba6a-5c637115dcfc
- date added to LUP
- 2020-05-12 12:30:03
- date last changed
- 2024-01-02 10:42:54
@article{d07b4c00-8159-4b8c-ba6a-5c637115dcfc,
abstract = {{<p>This study tested the effect of repeated intratumoural injection with recombinant interleukin-2 (rIL-2) and tumour-infiltrating lymphocytes (TILs) on inhibition of growth of breast cancer and on induction of apoptosis of tumour cells. The tumour cell line LDLX43 was used to induce breast cancer in Wistar rats. Group I (10 rats) was the control. Group II (12 rats) received repeated intratumoural injection with rIL-2 and TILs, rIL-2 at the dose of 5 x 10<sup>5</sup> IU/day was given for 7 days, and 1 x 10<sup>7</sup> TILs were injected on the second day of each rIL-2 therapy, for a treatment session, Overall, two treatment sessions of immunotherapy with rIL-2 and TILs were given in all treated animals. Rapid increased tumour volume was found in the control group. In the treated group the total response rate was 42%, of which 25% rumours showed partial regression and 17% tumours reached complete remission where infiltration of plenty of T lymphocytes was detected, indicating that T cell-mediated antitumour immunity is primarily responsible for tumour rejection. Further investigation showed the repeated immunotherapy using intratumoural injection with rIL-2 and TILs could induce the development of apoptosis of breast cancer cells.</p>}},
author = {{Liu, David L. and Yang, M. Q. and Eberhardt, J. and Persson, B.}},
issn = {{0304-3835}},
keywords = {{Apoptosis; Breast cancer; Cytokine; Immunohistology; Immunotherapy; Interleukin-2; Tumour-infiltrating lymphocytes}},
language = {{eng}},
month = {{06}},
number = {{2}},
pages = {{131--136}},
publisher = {{Elsevier}},
series = {{Cancer Letters}},
title = {{Repeated immunotherapy using intratumoural injection with recombinant interleukin-2 and tumour-infiltrating lymphocytes inhibits growth of breast cancer and induces apoptosis of tumour cells}},
url = {{http://dx.doi.org/10.1016/0304-3835(96)04195-X}},
doi = {{10.1016/0304-3835(96)04195-X}},
volume = {{103}},
year = {{1996}},
}